Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
The Experimental Drug and Therapeutics for Pediatric Brain Tumor Lab is looking at the STAT3 pathway as a new therapeutic target for treating malignant brain tumors.
The goal of this project is to develop new drugs and therapies for children with DIPGs by understanding the role of histone mutation in DIPG tumor cells.
Dr. Daniels' team is discovering that regulating glutamine metabolism may represent a new therapeutic approach for gliomas with this mutation.
The Experimental Drug and Therapeutics for Pediatric Brain Tumor Lab is identifying drugs for rapid clinical translation to develop molecularly targeted therapies for DIPG.
Dr. Daniels' lab is studying the feasibility of using convection-enhanced delivery to bypass the blood-brain barrier and distribute drugs directly to a target region.
Funding for Dr. Daniels' pediatric brain tumor research comes from the National Institutes of Health, the National Cancer Institute and Mayo Clinic.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.